Walter L. Longo, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Walter Longo is a tenured transplant physician for the adult bone marrow transplant program. His fellowship began in 1982, and in 1986 Dr. Longo joined the faculty of the UW School of Medicine and Public Health. In conjunction with the other transplant physicians, he provides inpatient and outpatient care for adult transplant patients as well as outreach clinical services in Portage, Wisconsin. In addition, Dr. Longo has developed autologous and allogeneic transplant protocols for several hematologic diseases and has acted as principal investigator on multi-institution, industry-related clinical trials.
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
UW Hospital and ClinicsUniversity of Wisconsin Hospital and Clinics
Mayo Clinic, Rochester, MN
Mayo Clinic, Rochester, MN
University of Nebraska Medical Center, Omaha, NE, 1977
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Longo's current research activities include immunotherapy after hematopoietic stem cell transplantation, non-myeloablative stem cell transplantation, and treatment of myelodysplastic syndromes and acute myelogenous leukemia.
Callander N Markovina S Eickhoff J Hutson P Campbell T Hematti P Go R Hegeman R Longo W Williams E Asimakopoulos F Miyamoto S .
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Aug 29;
[PubMed ID: 25168296]
Simondsen KA Reed MP Mably MS Zhang Y Longo WL .
Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2013 Dec;19(4):291-7
[PubMed ID: 23184539]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS .
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Chang JE Seo S Kim KM Werndli JE Bottner WA Rodrigues GA Sanchez FA Saphner TJ Longo WL Kahl BS .
Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):379-84
[PubMed ID: 21030351]
Chang JE Medlin SC Kahl BS Longo WL Williams EC Lionberger J Kim K Kim J Esterberg E Juckett MB .
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307
[PubMed ID: 19052977]
Agriantonis DJ Perlman SB Longo WL .
F-18 FDG PET imaging of GVHD-associated polymyositis. Clin Nucl Med. 2008 Oct;33(10):688-9
[PubMed ID: 18806568]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL .
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]
Kujawski LA Longo WL Williams EC Turman NJ Brandt N Mosher DF Eickhoff JC Kahl BS .
A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest. 2007 Mar;25(2):87-93
[PubMed ID: 17453819]
Fenske TS Kahl BS Eickhoff J Mitchell TL Smith EP Atkinson E McCoy AG Eckstein L Flynn B McMannes J Howard S Longo WL .
Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma. 2005 Oct;46(10):1441-8
[PubMed ID: 16194889]
Kahl BS Bailey HH Smith EP Turman N Smith J Werndli J Williams EC Longo WL Kim KM McGovern J Jumonville A .
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005;23(1):13-8
[PubMed ID: 15779863]